Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

A study found that disruptions in homeostasis from quick weight reduction by consuming GLP-1 drug can elevate cortisol - a ...

This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

A Danish study has found that semaglutide, which controls blood glucose while ensuring weight loss, is associated with a ...

However, a third drug also FDA-approved for weight loss, liraglutide (Saxenda), didn’t work as well as the others, ...

"It was the strangest feeling, because I never felt better about my physical appearance, but I also didn't want my husband to ...

In a world grappling with obesity and chronic disease, GLP-1 drugs like Ozempic are emerging as transformative game-changers. Initially designed for diabetes, these medications now promise ...

Liraglutide improves blood sugar levels by creating similar effects in the body as GLP-1 in the pancreas, which is often found in insufficient levels in those with type 2 diabetes. The prescribing ...

Insurers and self-funded employers are making significant changes to their GLP-1 drug coverage policies in 2025, reflecting the financial and operational challenges posed by the high-cost medications.

The glucagon-like peptide-1 (GLP-1) receptor agonist is designed to enhance glycemic control in adults and children 10 years and older with type 2 diabetes, complementing diet and exercise regimens.